GlassScriptPhysician profile
Carlena Plunkett
NPI 1770035362
$2,325.27
in general payments reported to CMS, 2019-2025
26 companies · $2,325 in 2025
The $2,325 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $310.12 | 2025 | Wegovy, Rybelsus, Ozempic |
| Corcept Therapeutics | $288.21 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $197.94 | 2025 | |
| Amgen INC. | $184.38 | 2025 | Tepezza, Repatha |
| Mannkind Corporation | $145.72 | 2025 | |
| Insulet Corporation | $140.28 | 2025 | Omnipod |
| Lilly USA, LLC | $137.49 | 2025 | Jardiance, Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $114.64 | 2025 | Recorlev |
| Tandem Diabetes Care, INC. | $111.19 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $110.46 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $82.97 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $76.31 | 2025 | Isturisa |
| Radius Health, INC. | $51.63 | 2025 | Tymlos |
| Abbott Laboratories | $51.56 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $51.16 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $50.11 | 2025 | Tryngolza |
| Novartis Pharmaceuticals Corporation | $37.32 | 2025 | |
| Dexcom, INC. | $29.39 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $27.31 | 2025 | Nexletol |
| Amphastar Pharmaceuticals, INC. | $21.35 | 2025 | |
| Cequr Corporation | $20.04 | 2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $19.59 | 2025 | Twiist |
| Ibsa Pharma INC. | $17.19 | 2025 | Flector, Tirosint, Licart |
| Antares Pharma, INC. | $16.75 | 2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2025 | Jardiance |
| Abbvie INC. | $15.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlena Plunkett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.